Skip to main content
. Author manuscript; available in PMC: 2018 Aug 10.
Published in final edited form as: Oncogene. 2016 Apr 4;35(40):5295–5303. doi: 10.1038/onc.2016.70

Figure 3. AMPK signaling is required for the activation of vemurafenib-induced autophagy.

Figure 3.

(a) Fluorescence images and quantification of GFP-LC3B labeled autophagosomes in YUKSI cells treated with DMSO, 1 μΜ vemurafenib, 1 mM AICAR, or both vemurafenib and AICAR. Data represent meants.e.m. across three fields of view ( · 75 cells in each condition; **P<0.01). (b) YUKSI melanoma cells expressing control or shAMPK were cultured with or without vemurafenib for 24 and 48 h. Levels of pAMPK, pULK1 and LC3B (examined on a 12% Bis-Tris gel) are shown. (c) Fluorescence images and quantification showing GFP-LC3B labeled autophagosomes in shCntrl or shAMPK expressing YUKSI cells treated with DMSO or vemurafenib. Data represent mean±s.e.m. (shCntrl/DMSO n=55 cells, shCntrl/Vem n=41 cells, shAMPK/DMSO n=36 cells, shAMPK/Vem n=61 cells; *****P<0.00001 log-rank test).